Skip to main content
  • Despite Wide Use, No Coronary Vasomotor Dysfunction Improvement in ANOCA Patients Given Diltiazem vs. Placebo: EDIT-CMD Study

    Diltiazem did not improve coronary vasomotor dysfunction (CVDys) versus placebo for angina and no obstructive coronary artery disease (ANOCA) patients treated for 6 weeks, despite frequently being recommended for these patients.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details